It was announced today that ZonMw expects to launch a new call for proposals in September under the PharmaNL Shared Development Infrastructure (SDI) programme line.
PharmaNL’s ‘Shared Development Infrastructure’ programme line focuses on establishing or expanding infrastructure for the development, scale-up, and production of innovative medicines in the Netherlands. Keep an eye on the ZonMw and PharmaNL websites for the exact opening date.
Projects must align with the priority themes outlined in PharmaNL’s revised 2026 investment agenda.
The PharmaNL programme is an initiative by and for the Dutch pharmaceutical sector. It is a national public-private consortium comprising Leiden University, Campus Groningen, and Pivot Park, working in close collaboration with FAST (Centre for Future Affordable Sustainable Therapy Development). PharmaNL aims to strengthen the pharmaceutical value chain in the Netherlands and remove bottlenecks.
PharmaNL is made possible through investments from its partners and an award from the National Growth Fund.
What if a surgeon could tell within five minutes whether a tumour has been completely removed? That is exactly what LIFE Cooperative member SPCTR is working on. In the Groninger Ondernemers Courant, the SPCTR team talks about their groundbreaking technology, which will allow surgeons to see within five minutes whether a tumour has been completely removed.
Following the keynote by Peter Wennink, the conversation continues with a panel discussion in which we will explore the themes from the keynote in further depth and look at the issues from different perspectives.
MimeCure heeft een investering van 3 miljoen euro binnengehaald voor de ontwikkeling van een regeneratief geneesmiddel voor de behandeling van chronische longziekten, zoals longfibrose. Dankzij deze financiering kan MimeCure de afronding van de preklinische fase versnellen en beginnen met de voorbereidingen voor klinische proeven, die volgens planning eind 2027 van start zullen gaan. De investeringsronde wordt geleid door Addington Investment Group en ondersteund door mede-investeerder Apsara Investments.
